The anti-tumor activity with IPH5201 has been shown in animal models involving human CD39 knock-in mice injected with melanoma cell lines (B16F10) with researchers able to link the blocking of ATP hydrolysis through inhibition of both membrane and soluble CD39 to the subsequent activation of TAMs and DCs [280]. Here, ENTPD1 is linked to neoplasm.